AVDL:NSD-Avadel Pharmaceuticals plc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 6.75

Change

0.00 (0.00)%

Market Cap

USD 0.39B

Volume

0.19M

Average Target Price

N/A
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Avadel Pharmaceuticals plc operates as a specialty pharmaceutical company in the United States, France, and Ireland. The company primarily develops FT218, which is in a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy. It also markets three sterile injectable drugs used in the hospital setting, including Akovaz that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia; Bloxiverz, a cholinesterase inhibitor indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; and Vazculep, a phenylephrine hydrochloride injection indicated for the treatment of clinically important hypotension. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland. Address: 10 Earlsfort Terrace, Dublin, Ireland, 2

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-24 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
CGC Canopy Growth Corporation

N/A

USD12.70B N/A N/A
MYL Mylan N.V

N/A

USD8.59B 30.73 11.86
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.24B N/A N/A
APHA Aphria Inc

N/A

USD4.12B 43.21 454.68
CRON Cronos Group Inc

N/A

USD3.82B 37.11 N/A
PCRX Pacira BioSciences, Inc

N/A

USD2.95B 23.15 63.56
TLRY Tilray, Inc

N/A

USD2.85B N/A N/A
IRWD Ironwood Pharmaceuticals, Inc

N/A

USD1.66B 14.79 12.38
ENDP Endo International plc

N/A

USD1.60B N/A 9.94
SUPN Supernus Pharmaceuticals, Inc

N/A

USD1.58B 12.42 7.90

ETFs Containing AVDL

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.05% 22% F 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.05% 22% F 26% F
Trailing 12 Months  
Capital Gain -2.03% 56% F 36% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.03% 56% F 33% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 44.10% 95% A 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 44.10% 95% A 88% B+
Risk Return Profile  
Volatility (Standard Deviation) 161.35% 4% F 6% F
Risk Adjusted Return 27.33% 75% C 53% F
Market Capitalization 0.39B 54% F 47% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 20.83 48% F 47% F
Price/Book Ratio 2.30 73% C 58% F
Price / Cash Flow Ratio -10.26 72% C- 75% C
EV/EBITDA 23.68 42% F 37% F
Management Effectiveness  
Return on Equity 21.59% 96% A 92% A-
Return on Invested Capital -17.77% 60% D- 29% F
Return on Assets -7.61% 58% F 30% F
Debt to Equity Ratio -416.75% 79% C+ 98% A+
Technical Ratios  
Short Ratio 7.33 34% F 14% F
Short Percent N/A N/A N/A N/A N/A
Beta 1.55 37% F 29% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.